Menu

Current Clinical Trials

We are currently enrolling participants in the following studies:

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -


Ulcerative Colitis 


Takeda (Vedolizumab) Protocol MLN 0002-3026


 

  • An Efficacy and Safety Study of Vedolizumab (Entyvio) Intravenous (IV) Compared to Adalimumab (Humira) subcutaneous (SC) in Participants With Ulcerative Colitis
  • Purpose: The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) treatment over a 52-week treatment period.
  • More info HERE


Gilead (Filgotinib) Protocol GS-US-418-3898 & GS-US-418-3899 (OLE) 


 

  • Filgotinib in the Induction and Maintenance of Remission in Adults with Moderately to Severely Active Ulcerative Colitis
  • Purpose: The purpose of this study is to evaluate the safety and efficacy of filgotinib in the induction and maintenance treatment to severely active ulcerative colitis (UC) in participants who are biologic-naive and biologic-experienced.
  • Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to enter a separate, long-term extension (LTE) study (Gilead Study GS-US-418-3899
  • More info HERE. 

 

Crohn's Disease


Takeda (Vedolizumab) Protocol MLN 3031


 

  • Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
  • Purpose: The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) as maintenance treatment in participants with moderately to severely active Crohn's disease (CD) who achieved clinical response following administration of vedolizumab intravenous (vedolizumab IV) induction therapy.
  • More info HERE.


MedImmune (MEDI2070) Protocol D5170C00002


 

  • Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
  • Purpose: A Phase 2b study to evaluate the efficacy and safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
  • More Info HERE.


 

2645 N. Mayfair Road, Suite 200  * Wauwatosa, WI 53226    P. 414.727.8131    F.414.479.1811

Home   ·   About Us   ·   Current Studies   ·  Volunteer   ·  Contact Us

Text/HTML

LIKE US              FOLLOW US  

Address:  2645 N. Mayfair Road - Suite 200 * Wauwatosa, WI 53226

Phone:  414.727.8131

Fax:  414.479.1811

Email:  research@arsmke.com